Flagship cancer therapy offers promise of potential side effects reduction

Medical technology company Terumo Blood and Cell Technologies and clinical-stage biotech Immunicom have signed a co-commercialisation agreement to advance a breast cancer therapy with potential to limit treatment–related adverse effects.

This is achieved by removing immune inhibitors from a patient’s bloodstream, which could help their immune system to more effectively attack cancer tumours. 

This subtractive therapy approach, which combines Terumo’s Spectra Optia(R) Apheresis System with Immunicom’s immuno-oncology LW-02 Column, is intended for patients with aggressive advanced refractory triple-negative breast cancer (TNBC), which accounts for approximately 15 percent of all breast cancers. Under the agreement, Terumo will also become the exclusive distributor in Germany, France, Italy, and Spain with potential for future geographic expansion.

 “Terumo Blood and Cell Technologies has supported Immunicom from its beginning in 2013,” said Amir Jafri, Founder and CEO of Immunicom. “With their strong global presence and shared commitment to advancing standards of care through innovation, they were the natural choice to strategically partner with on the international commercialisation of our flagship immunotherapy offering. With the LW-02 Column being only the first of many platform-based subtractive therapies under development at Immunicom, we see very strong long-term growth potential in further expanding this relationship.” 

“Imagine if someone who is battling late-stage breast cancer could mitigate the effects of chemotherapy, spending their final days actively engaging with those they love, shaping their final memories,” said Antoinette Gawin, President and Chief Executive Officer, Terumo Blood and Cell Technologies. “That’s why we are combining our technology with Immunicom’s – to bring this to life.”

More information online